Group 1: Company Overview - Beijing Wanbangda Environmental Technology Co., Ltd. was established in 1998, initially focusing on industrial wastewater treatment in the petrochemical sector [1] - The company has transitioned into the chemical new materials field through investments in Huizhou Yisike, leveraging its Guangdong Yisike (Jieyang) base for high-end new material development [1][2] Group 2: Product Development and Competitive Advantages - The new TPE synthetic leather products feature innovative molecular structure design, offering various properties such as skin-friendly, environmentally friendly, wear-resistant, and flame-retardant characteristics [2] - The Jieyang project will produce key products including isoprene, pentadiene, and SBS/SEBS/SIS/SEPS, which will be used in adhesives, rubber, and other applications [3] Group 3: Project Progress and Production Capacity - The Jieyang project is set to begin construction in 2024 and aims for trial production in 2025, with three production units planned: a 250,000 tons/year carbon five separation unit and two 30,000 tons/year SBS/SEBS/SIS/SEPS units [2] - The carbon five separation unit has already entered trial production, while other units are in the commissioning phase [2] Group 4: Research and Development - The company has built a research team of over a hundred members, combining experienced experts and project leaders with younger developers [4] - Approximately 60% of current research projects focus on cutting-edge new materials [5] Group 5: Sales Strategy - The sales strategy for new products targets large clients and relies on distributors, gradually building a sales network through key partnerships [5]

Group 1: Company Overview - Wanma Technology Co., Ltd. was established in 1997 and listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 31, 2017 [3] - In the first three quarters of 2025, the company achieved a revenue of CNY 557 million, representing a year-on-year growth of 44.51% [3] - The company has two main business segments: communication and industrial control, and vehicle networking, both of which have seen rapid growth [3] Group 2: Business Development - The company is actively expanding its product offerings in the distribution sector, becoming a candidate for three projects with the State Grid, with a total bid amount of CNY 81.2742 million in 2025 [4] - In the vehicle networking sector, the company has connected over 17 million vehicles globally, with significant partnerships with major automotive manufacturers such as Geely and Li Auto [5] Group 3: Competitive Advantages - Wanma Technology leverages partnerships with major telecom operators (China Mobile, China Telecom, China Unicom) to provide robust communication infrastructure [4] - The company has developed advanced networking solutions, including dual SIM and AI network technologies, to meet the high bandwidth and low latency requirements of smart connected vehicles [5] Group 4: Future Market Potential - The Robotaxi market is projected to reach USD 116 billion by 2030, while the domestic logistics market for Robovan is expected to see significant growth, with potential increases of CNY 977 billion and CNY 1,416 billion respectively [6] - The company is focusing on the commercial viability of autonomous driving applications, positioning itself to capitalize on the expected growth in these sectors [6] Group 5: Product Offerings - Wanma Technology provides comprehensive solutions for the vehicle networking sector, including hardware, eSIM solutions, and AI-driven cloud services [7] - The company has established partnerships with various firms in the Robotaxi and Robovan sectors, including Baidu Apollo and Hello Chuxing [7] Group 6: Global Expansion - The company has deployed six major data platforms globally and has established branches in regions such as Europe and the Middle East to enhance service efficiency and compliance [8] - Wanma Technology's platform supports multiple eSIM standards, enabling it to handle large-scale operations for multinational automotive brands [8]

证券代码：000768 证券简称：中航西飞 三、请问 2025 年度国际转包业务的增长情况？ 目前公司国际转包业务运营稳中有进，以与空客公司合作为 例，公司把握空客天津第二条总装线投产契机，紧盯空客总装线速 率爬坡计划，扩大与空客现有项目合作规模，积极争取 A320 系列 项目合作增量。深入发挥公司作为空客一级供应商的管理效能，全 面开展全价值链产能准备工作，从人员、工装、设备等多方面、多 维度识别上速率瓶颈，确保速率提升稳步实现。 中航西安飞机工业集团股份有限公司 投资者关系活动记录表 编号：2025-012 | 投资者关系 | 特定对象调研 分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 路演活动 | | | □现场参观 □其他（请文字说明其他活动内容） 长江证券、易方达基金、国投瑞银基金、交银施罗德基金、华安基 | | | 金、鹏扬基金、华泰资产、百年资管、太平养老、人保资产。 | | 活动参与人员 | 上市公司参与人员： | | | 董事长韩小军、董事会秘书左锋、证券事务代表龚亮、财务管理部 | | | 副书记苏博、证券与资本管理 ...

Group 1: Company Overview and Financial Performance - Fujian Snowman Group Co., Ltd. was established in 2000, focusing on advanced equipment manufacturing in cold chain logistics, industrial refrigeration, clean energy, and hydrogen power sectors [1] - In the first three quarters of 2025, the company achieved a revenue of CNY 1.631 billion, representing a year-on-year increase of 24.26% [1] Group 2: Controlled Nuclear Fusion Business - The company is involved in the controlled nuclear fusion sector, utilizing helium compressors as core components for large-scale low-temperature systems [1] - The "large-scale low-temperature refrigeration system" project employs the company's "megawatt-level" helium compressor, capable of achieving cooling at -271°C with a cooling capacity of 100 watts [2] - The technology has received national scientific achievement evaluation, reaching an internationally leading level with significant social and economic benefits [2] Group 3: Hydrogen Energy Sector - The company has developed a long-term strategy in the hydrogen fuel cell sector, focusing on core technologies within the supply chain [3] - It has established hydrogen technology R&D institutions in Europe and Japan, working on key components and materials for hydrogen fuel cells [3] - The company is advancing the mass production of hydrogen fuel cells and core components, gradually building a complete industrial ecosystem [3] Group 4: Data Center Business Expansion - The company has entered the data center sector, leveraging its compressor technology to offer a diverse product line, including piston, open-type screw, semi-closed screw, and centrifugal compressors [4] - It has implemented low-charge ammonia refrigeration technology in overseas data centers, providing energy-efficient and environmentally friendly solutions [4] - The company’s subsidiary, Hangzhou Longhua, is involved in major data center refrigeration engineering projects for leading enterprises like China Mobile and Alibaba [4] Group 5: Ice Making Products Development - The company has seen significant growth in its ice-making products, particularly in the industrial construction and ice and snow sectors [5] - Demand in the Middle East for large-scale infrastructure projects is expected to drive rapid growth in the industrial construction sector over the next three to five years [5] - The company's ice-making and snow-making products are utilized in over 30 global ice and snow projects annually, establishing a stable business foundation [5] Group 6: Future Outlook - The company aims to continue expanding application scenarios and strengthening technological advantages while seizing opportunities in national strategies and global trends [5] - It plans to leverage innovative products and comprehensive service capabilities to drive steady business growth [5]

Group 1: Company Overview - The company specializes in the research, production, and sales of IoT intelligent products, focusing on communication, positioning, and AI technologies [1] - It aims to become a global expert in IoT intelligent application solutions, adhering to the mission of "empowering wisdom for a better future" [1] Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 1.402 billion, a year-on-year increase of 24.85%, and a net profit of CNY 176 million, up by 0.81% [2] - For the first three quarters of 2025, the company reported a revenue of CNY 1.272 billion, a 21.66% increase year-on-year, and a net profit of CNY 180 million, reflecting a 33.95% growth [2] Group 3: Market Outlook - The demand for smart vehicle terminals and smart sleep terminals is expected to continue growing, supported by favorable market conditions [2] - The installation penetration rate of smart vehicle video recorders in the domestic heavy-duty truck sector is currently low, indicating potential growth opportunities [2] Group 4: International Expansion - The company is leveraging the "Belt and Road" initiative to expand its market presence in Africa, Southeast Asia, and Central Asia, while also targeting developed markets in Europe and North America [3] - It has successfully entered the supplier system of an overseas automotive brand, beginning small-scale supply [3] Group 5: Product Diversification - The company has diversified its product offerings across various scenarios, including smart transportation, smart sleep, and mobile payment, with a focus on customer-driven solutions [4] - The smart sleep terminal can track and analyze users' sleep states, adjusting the environment for optimal sleep quality [5] Group 6: Core Competencies - The company's ability to adapt technology to various application scenarios is a key strength, supported by extensive experience in core technologies such as communication, positioning, and AI [4] - The fragmented nature of the IoT market allows the company to customize solutions effectively, enhancing product competitiveness [4] Group 7: Supply Chain Management - Storage chips are primarily used in commercial vehicle monitoring terminals, with their cost impact on the company being relatively low due to existing reserves [6]

Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of CNY 30.654 billion, a year-on-year increase of 2.47% [2] - Net profit attributable to shareholders reached CNY 4.777 billion, exceeding the full-year 2024 figure of CNY 4.749 billion, with a year-on-year growth of 10.41% [2] - Non-recurring net profit was CNY 4.550 billion, surpassing the 2024 full-year figure of CNY 4.523 billion, reflecting a year-on-year increase of 6.68% [2] - The weighted average return on equity was 11.92%, up by 1.10 percentage points year-on-year [2] - Operating cash flow net amount reached CNY 4.456 billion, a year-on-year increase of 9.40% [2] - As of the end of the period, cash and cash equivalents totaled CNY 8.618 billion, with a debt-to-asset ratio of 25.36% [2] Pharmaceutical Business Development - The pharmaceutical division implemented integrated marketing strategies focusing on various scenarios, achieving over 20% growth in O2O sales [4] - Online sales during the 2025 "618" shopping festival saw significant improvements, with 48.45 million visitors and a GMV of CNY 254 million [4] - Clinical research on products like Yunnan Baiyao (powder) and capsules for diabetes foot and bone pain showed steady progress [4] Health Products Performance - The health products division maintained its leading market share in toothpaste, while the brand "Yangyuanqing" ranked first in Tmall for anti-hair loss shampoo during the 2025 "618" period [6] Acquisition and Integration Strategy - The acquisition of Juyitang aims to enhance the company's capabilities in the traditional Chinese medicine sector, with a production capacity of 25,000 tons for herbal pieces and 1,500 tons for formula granules [7] - Juyitang's established online sales channels and large B-end customer base are expected to provide strategic synergies and improve operational efficiency [7] Research and Development Pipeline - The company is focusing on secondary innovation and rapid drug development, with 16 major traditional Chinese medicine projects and 37 ongoing projects [8] - Key projects include the completion of Phase II clinical trials for Sanqi tablets and the initiation of Phase III trials for various products [8] - Long-term projects include the launch of clinical trials for innovative drugs and monoclonal antibody projects [8]

编号：38-2512-03 | | 特定对象调研 □分析师会议 ☑ | | | | --- | --- | --- | --- | | | □媒体采访 □业绩说明会 | | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | | 现场参观 □一对一沟通 ☑ | | | | | □其他（电话会议） | | | | | 江西知风咨询-杨明，广东臻远私募基金-刘汉顶、沈勇，珠海横 琴天勤-孙慧敏，深圳蓝马资本-刘柯，广东邦政资产-安德生， | | | | 参与单位名称及人员 | 广州林正投资-叶华东，扬州润毅创投-李仁武、文川，山东海润 | | | | 姓名 | 投资-刘冠秀，益和源资产-雷学成、胡祥林，江西天伦-刘国庆， | | | | | 个人投资者-郭大力、胡德安 | | | | 时间 | 年 月 2025 11 | 12 | 日 | | 地点 | 集团总部办公大楼 | | | | 上市公司接待人员 | 投资者关系管理-张昱、杨可欣、余洋 | | | | 投资者关系活动主要 | 了解公司生产经营情况 | | | | 内容介绍 | | | | | 附件清单 | 会议记录 | | | | 日 ...

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from various investment firms and individual investors [2] - The meeting took place on December 10, 2025, at the company's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2]

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

证券代码：301632 证券简称：广东建科 广东省建筑科学研究院集团股份有限公司 投资者关系活动记录表 答：公司重视科技创新和数字化转型，近三年主营业务研发费 用率呈现逐年上升趋势，主要投入于行业战略性、前沿性领域的研 发，绿色低碳科技研究等方面的研究。截至 2025 年 6 月 30 日，公 编号：2025-021 投资者关系 活动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑ 现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 广州泽恩投资 曹盈盈 松山创业投资 吴德有 深圳中天汇富基金管理有限公司 何佑胜 广东金豆子 马杰辉 深圳诚和昌私募基金投资有限公司 戴九侯 中金资本 刘弦 灏达投资 资香莲 乐盈(珠海)私募证券投资公司 鲍传广 东北证券 吴源恒 广州市摩星岭控股有限公司 董佳宁 广州南杰利私募基金 林小峰 广州瑞民基金 罗小明 广新基金 赖增强 中大情私募基金管理有限公司 刘剑荣 广东凯鼎投资有限公司 甄义勇 华福证券 王二鑫 润生投资 汪江涛 乐盈投资 李俊 时间 2025 年 12 月 12 日（星期五）14:00-16:30 ...